Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528105) titled 'Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes' on April 7.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Zhongshan Hospital

Condition: T1DM - Type 1 Diabetes Mellitus

Intervention: Biological: Allogeneic CD7-Targeted CAR-T Cell Injection

Recruitment Status: Recruiting

Phase: Early Phase 1

Date of First Enrollment: April 2026

Target Sample Size: 9

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07528105

Disclaimer: Curated b...